Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 3
2023 pubmed 15 citations

The LL-37 Antimicrobial Peptide as a Treatment for Systematic Infection of <i>Acinetobacter baumannii</i> in a Mouse Model.

Zarei-Mehrvarz. Ehsan E; Fahimirad. Shohreh S; Ghaznavi-Rad. Ehsanollah E; Abbasian. Shabnam Sadoogh SS; Abtahi. Hamid H

Key Findings

  • LL‑37 killed A. baumannii at a low dose of 1.5 µg/mL in vitro
  • The peptide wiped out the bacteria within 40 minutes in time‑kill tests
  • All mice treated with LL‑37 survived systemic infection and had no detectable bacteria in their blood

Practical Outcomes

  • LL‑37 looks promising as a powerful, fast‑acting antimicrobial, but it’s currently only available as a recombinant protein made in a lab. For biohackers, it suggests a potential future therapy worth watching, though practical use would require peptide synthesis, dosing studies, and safety testing before it could be self‑administered.

Summary

Researchers made a lab‑produced version of the human peptide LL‑37 and showed it can quickly kill the dangerous bacteria Acinetobacter baumannii in test tubes and save mice with a bloodstream infection, with no bacteria left in their blood.

Abstract

The antimicrobial peptides (AMPs) played a critical role in the innate immunity of the host and are considered natural sources illustrating a broad-spectrum antimicrobial activity with high specificity and low cytotoxicity. AMPs generally possess a net positive charge and have amphipathic structures. Thus, AMPs can bind and interact with negatively charged bacterial cell membranes, leading to destructive defects in biomembranes and ending in cell death. LL37 is the only human cathelicidin-derived antimicrobial peptide that shows a broad spectrum of antimicrobial activity. To determine the antibacterial efficiency of LL37 in a mouse model of systemic A. baumannii infection, LL37 corresponding gene was expressed in E. coli, purification and refolding situations were optimized. The antimicrobial performance of produced LL-37 against A. baumannii was evaluated in vitro via MIC and Time Kill assays, and its destructive effects on the bacterial cell were confirmed by SEM image. The recombinant LL37 showed strong antibacterial function against A. baumannii at 1.5 &#x3bc;g/mL concentration. Time kill assay showed a sharp reduction of cell viability during the first period of exposure, and complete cell death was recorded after 40 min exposure. Furthermore, in vivo results represented a significant ability of LL37 in the treatment of systematic infected mouse models, and all infected mice receiving LL37 protein survived without no trace of bacteria in their blood samples.

Study Information

Provider

pubmed

Year

2023

Date

2022-09-29T00:00:00.000Z

DOI

10.2174/0929866529666220929160704

Citations

15